Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor
Fiona Elwood(Merck & Co., Inc., Rahway, NJ, USA (United States)), David J. Witter(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jennifer Piesvaux(Merck & Co., Inc., Rahway, NJ, USA (United States)), Brian Kraybill(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nathan Bays(Merck & Co., Inc., Rahway, NJ, USA (United States)), Carla Alpert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter Goldenblatt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yujie Qu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Irena L. Ivanovska(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hyun‐Hee Lee(Merck & Co., Inc., Rahway, NJ, USA (United States)), Chi‐Sung Chiu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hao Tang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mark E. Scott(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sujal V. Deshmukh(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mark Zielstorff(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alan Byford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kalyan Chakravarthy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lauren Dorosh(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alexey Rivkin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joel A. Klappenbach(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bo‐Sheng Pan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ilona Kariv(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher J. Dinsmore(Merck & Co., Inc., Rahway, NJ, USA (United States)), Deborah Slipetz(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter J. Dandliker(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 32
Abstract
Related Papers
No related papers found
Powered by citation graph analysis